Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471964 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01471964 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 22 participants.
The verdict
NCT01471964, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and the best dose of MLN8237 when given together with erlotinib hydrochloride and to see how well it works in treating patients with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC). MLN8237 and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG MLN8237 and Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-10-20 |
| Est. Completion | 2018-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471964
The ClinicalTrials.gov registry entry for NCT01471964 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MLN8237 and Erlotinib is the first listed.
NCT01471964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01471964 about?
NCT01471964 is a clinical study titled "Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer". This phase I/II trial studies the side effects and the best dose of MLN8237 when given together with erlotinib hydrochloride and to see how well it works in treating patients with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC). MLN8237 and erlotinib may stop the growth o...
What is the current status of trial NCT01471964?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-10-20. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT01471964?
The interventions under investigation include: MLN8237 and Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01471964?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.